AusperBio raises US$120M to advance Hepatitis B therapies toward functional cure

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.